In various models, CX-5461 has been shown to activate ATM/ATR signaling and the combination of CX-5461 with dual inhibition of CHK1/2 has been reported to significantly enhance the therapeutic outcome against p53-null MYC-driven lymphoma in vivo [88]. The gene discussed is MYC; the disease is lymphoma.